Index

acute urinary retention (AUR) 83
\( \alpha \)-adrenergic receptor antagonists 83
5\( \alpha \)-reductase inhibitors 93
antimuscarinics 104, 106–109
clinical assessment and diagnosis 40
combination therapy 136–140, 145–147
watchful waiting 61–62
ADAM see Alphablocker in Men
Agency for Health Care Policy and Research (AHCPR) 23
AH see autonomic hyperactivity
AHCPR see Agency for Health Care Policy and Research
alfuzosin 14, 75–76, 78–79, 114, 124, 125, 134, 147
\( \alpha \)-adrenergic receptor antagonists 70–89
adverse effects 73, 75–76, 81–82, 84–85, 133, 140–142, 145–147, 149
alfuzosin 14, 75–76, 78–79, 114, 124, 125, 134, 147
\( \alpha \)-adrenergic receptors in the prostate 72
clinical trials 2–3, 78, 81–83, 85
combination therapy 78, 80–84, 124–125, 129–142
concepts and definitions 70–72
doxtazosin 3, 73, 78, 80–83, 85, 124–125, 135–140
intraoperative floppy iris syndrome 79–80, 85
mechanism of action 129
naftopidil 77–78, 83–84
nonselective \( \alpha \)-blockers 72–73
selective \( \alpha \)-blockers 73–78
sexual dysfunction 75–76, 78–79, 84
silodosin 76–77, 79, 85
terazosin 73–74, 80, 85
Alphablocker in Men (ADAM) study 106
5\( \alpha \)-reductase inhibitors 90–99
adverse effects 94–95, 133, 140–142
clinical trials 2–3, 91–96
combination therapy 78, 80–83, 129–150
comparison between agents 94
congcepts and definitions 90
dutasteride 83, 85, 91–96, 136, 138–140
finasteride 3, 62, 78, 80–83, 91–96, 134–140
historical development 90–91
mechanism of action 129, 134
prostate cancer 95–96
rationale for use 91
American Urological Association Symptom Index (AUA-SI)
\( \alpha \)-adrenergic receptor antagonists 71, 74–77, 80–82
5\( \alpha \)-reductase inhibitors 93–94, 96
clinical assessment and diagnosis 26, 50
combination therapy 136–137
electrocautery-based techniques 203
epidemiologic studies 12, 16
GreenLight laser therapy 192–193
minimally invasive therapies 178
watchful waiting 60
amino acids 160
androgen regulation 3–4
ANS see autonomic nervous system
antibiotics 168–169
antimuscarinics 100–112
adherence and persistence 108
adverse effects 107–109, 145–147
algorithm of treatment and management 108–109
bladder outlet obstruction 101–102, 107, 108
clinical trials 104–107
comparison between agents 107
congcepts and definitions 100–101
darifenacin 107
mechanism of action 101–104
overactive bladder 100–103, 104–106
postvoid residual urine volume 104–108
practical aspects 108–109
solifenacin 106, 107
tolterodine 104–107, 142, 146
anxiety 12–13
apoptosis 158
AUA-SI see American Urological Association Symptom Index
AUR see acute urinary retention
autonomic hyperactivity (AH) 118–119
autonomic nervous system (ANS) 66
azuprostat 155–156
BACH see Boston Area Community Health
benign prostatic enlargement (BPE)
clinical assessment and diagnosis 22
epidemiologic studies 13
open simple prostatectomy 164
Benign Prostatic Hyperplasia Impact Index (BPH-II) 26–27
benign prostatic obstruction (BPO) 164, 168
β-sitosterol 155–156
biochanin A 156
biopsy 3
bipolar transurethral resection of the prostate (bTURP) 204–208
bladder calculi 29
bladder diaries 40, 54
bladder neck incision 186
bladder outlet obstruction (BOO)
antimuscarinics 101–102, 107, 108
clinical assessment and diagnosis 22, 25, 30–32, 40–41, 49
GreenLight laser therapy 198
phosphodiesterase type 5 inhibitors 117–118
watchful waiting 63–64
blood urea nitrogen (BUN) 53, 64
BMSFI see Brief Male Sexual Function Inventory
BOO see bladder outlet obstruction
Boston Area Community Health (BACH) Survey 12, 15–17
botulinum toxin A (BTX-A) 179–181
Carcinoma in situ (CIS) 29
cataract surgery 80
chemokines 4–6
chronic hypoxia 118–119
chronic kidney disease 64–65
chronic pelvic pain syndrome (CPPS) 5
chronic prostatitis (CP) 5
chronic urinary retention 31
CIS see carcinoma in situ
clinical assessment and diagnosis
algorithms for diagnosis and management 23–25, 41–42
assessment aims 38
characterization of IUTS and quality of life 23–27, 39
concepts and definitions 22–23, 37–38, 47–49
degree of bother 23–26, 30–31, 38–39, 42, 55–56
differential diagnosis after initial evaluation 29–30, 52
epidemiologic studies 11, 16–17
Europe 37–46
evaluation of persistent or complicated LUTS in males 30–32
flexible cystoscopy 32, 41
frequency–volume charts 40
health outcomes in Europe 42–44
imaging techniques 32, 41
informed surveillance 55–56
initial diagnostic tests 27–29, 40, 53–55
International Prostate Symptom Score 23–26, 39, 44, 50–51
medical history 23, 38–39, 50–53
normal/abnormal bladder function 49–50
normal/abnormal prostate function 49
physical examination and digital rectal examination 27, 39, 53
postvoid residual urine volume 31, 40–41, 53, 54–55
pressure–flow studies 31–32, 41–42
primary care 47–58
prostate-specific antigen testing 29, 40, 53–54
reasons for referral 55
serum creatinine 32, 40
transabdominal ultrasound 41
transrectal ultrasound of the prostate 32
United States 22–36
uroanalysis 27–29, 40, 53
uroflowmetry 30–31, 41
voiding/bladder diaries 29, 40, 54
Clostridium botulinum 179–181
carcinoma in situ (CIS) 29
cataract surgery 80
chemokines 4–6
chronic hypoxia 118–119
chronic kidney disease 64–65
chronic pelvic pain syndrome (CPPS) 5
chronic prostatitis (CP) 5
chronic urinary retention 31
CIS see carcinoma in situ
clinical assessment and diagnosis
algorithms for diagnosis and management 23–25, 41–42
assessment aims 38
characterization of IUTS and quality of life 23–27, 39
concepts and definitions 22–23, 37–38, 47–49
degree of bother 23–26, 30–31, 38–39, 42, 55–56
differential diagnosis after initial evaluation 29–30, 52
epidemiologic studies 11, 16–17
Europe 37–46
evaluation of persistent or complicated LUTS in males 30–32
flexible cystoscopy 32, 41
frequency–volume charts 40
health outcomes in Europe 42–44
imaging techniques 32, 41
informed surveillance 55–56
initial diagnostic tests 27–29, 40, 53–55
International Prostate Symptom Score 23–26, 39, 44, 50–51
medical history 23, 38–39, 50–53
normal/abnormal bladder function 49–50
normal/abnormal prostate function 49
physical examination and digital rectal examination 27, 39, 53
postvoid residual urine volume 31, 40–41, 53, 54–55
pressure–flow studies 31–32, 41–42
primary care 47–58
prostate-specific antigen testing 29, 40, 53–54
reasons for referral 55
serum creatinine 32, 40
transabdominal ultrasound 41
transrectal ultrasound of the prostate 32
United States 22–36
uroanalysis 27–29, 40, 53
uroflowmetry 30–31, 41
voiding/bladder diaries 29, 40, 54
Clostridium botulinum 179–181
carcinoma in situ (CIS) 29
cataract surgery 80
chemokines 4–6
chronic hypoxia 118–119
chronic kidney disease 64–65
chronic pelvic pain syndrome (CPPS) 5
chronic prostatitis (CP) 5
chronic urinary retention 31
CIS see carcinoma in situ
clinical assessment and diagnosis
algorithms for diagnosis and management 23–25, 41–42
assessment aims 38
characterization of IUTS and quality of life 23–27, 39
concepts and definitions 22–23, 37–38, 47–49
degree of bother 23–26, 30–31, 38–39, 42, 55–56
differential diagnosis after initial evaluation 29–30, 52
epidemiologic studies 11, 16–17
Europe 37–46
evaluation of persistent or complicated LUTS in males 30–32
flexible cystoscopy 32, 41
frequency–volume charts 40
health outcomes in Europe 42–44
imaging techniques 32, 41
informed surveillance 55–56
initial diagnostic tests 27–29, 40, 53–55
International Prostate Symptom Score 23–26, 39, 44, 50–51
medical history 23, 38–39, 50–53
normal/abnormal bladder function 49–50
normal/abnormal prostate function 49
physical examination and digital rectal examination 27, 39, 53
postvoid residual urine volume 31, 40–41, 53, 54–55
pressure–flow studies 31–32, 41–42
primary care 47–58
prostate-specific antigen testing 29, 40, 53–54
reasons for referral 55
serum creatinine 32, 40
transabdominal ultrasound 41
transrectal ultrasound of the prostate 32
United States 22–36
uroanalysis 27–29, 40, 53
uroflowmetry 30–31, 41
voiding/bladder diaries 29, 40, 54
Clostridium botulinum 179–181
cluster analysis 16–17
Combination of Avodart and Tamsulosin (CombAT) trial 83, 85, 136, 138–140
combination therapy 129–153
adverse effects 133, 140–142, 145–147, 149
α1-adrenergic receptor antagonists 78, 80–84, 104–106, 124–125, 129–150
5α-reductase inhibitors 78, 80–83, 129–142
antimuscarinics 104–106, 142–147
mechanisms of action 129, 134
meta-analysis 149
objective outcome measures 132, 146
phosphodiesterase type 5 inhibitors 124–125, 147–149
placebo-controlled and direct comparator studies 134–140
sexual dysfunction 141–142, 148–149
small studies of short duration 134
subjective outcome measures 130–131
systematic review 142–145
Complementary and Alternative Medicines for Urological Symptoms trial 158
complementary therapy 154–163
adverse effects 157
β-sitosterol 155–156
concepts and definitions 154
Cucurbita pepo L. 160
exercise 13, 160
flaxseed lignans 160
Hypoxis rooperi 159
isosflavones 156
nutrients 160
phyotherapy 155–160
Pygeum africanum 158–159
Secale cereale 159
Serona repens 156–158
Urtica dioica et urens 159
CP see chronic prostatitis
CPPS see chronic pelvic pain syndrome
Cucurbita pepo L. 160
Cyr61 5–6
cystometry 63–64
daidezein 156
Danish Prostate Symptom Score (DAN-PSS) 26, 39, 78, 114, 195
darifenacin 107
depression 12–13
detrusor overactivity (DO)
  α₁-adrenergic receptor antagonists 77
  antimuscarinics 100–103
clinical assessment and diagnosis 22, 30, 38, 41
watchful waiting 63–64
DHT see dihydrotestosterone
diabetes
  epidemiologic studies 11
etiology and pathogenesis 5
  watchful waiting 65
  see also metabolic syndrome
diagnosis see clinical assessment and diagnosis
Diagnosis Improvement in Primary Care Trial (D-IMPACT) study 44
digital rectal examination (DRE) 27, 39, 53, 62–63, 135
dihydrotestosterone (DHT) 4, 90–92, 158
D-IMPACT see Diagnosis Improvement in Primary Care Trial
DO see detrusor overactivity
doxazosin 3, 73, 78, 80–83, 85, 124–125, 135–140
DRE see digital rectal examination
dutasteride 83, 85, 91–96, 136, 138–140
EAU see European Association of Urology
ED see erectile dysfunction
ejaculatory dysfunction (EjD)
  α₁-adrenergic receptor antagonists 75–76, 78–79, 84
  5α-reductase inhibitors 94–95
  epidemiologic studies 11, 14–15
  GreenLight laser therapy 198
  phosphodiesterase type 5 inhibitors 114–116, 125
electrocautery-based techniques 201–210
  adverse effects 202–203, 206
  bipolar transurethral resection of the prostate (bTURP) 204–208
  concepts and definitions 201–202
  monopolar electrovaporization technology 203–204
  monopolar transurethral resection of the prostate 202–203, 207
EMT see epithelial-to-mesenchymal transition
end-stage renal disease (ESRD) 64, 66–67
Enlarged Prostate International Comparator Study (EPICS) 94–95
EPIC see European Prospective Investigation into Cancer and Nutrition
epidemiologic studies 10–21
  broad health outcomes and BPH/LUTS 12–13
  concepts and definitions 10–11
  descriptive epidemiology, risk factors, and correlates 11–16
  exercise 13
  measurement and classification of LUTS symptoms 11, 16–17
  men who have sex with men 14
  metabolic syndrome, obesity and LUTS 11–12
  phosphodiesterase type 5 inhibitors 114–116
  recent advances 11
  sexual dysfunction 11, 14–16
  sociodemographic and lifestyle factors 13
  systemic factors and inflammation 12, 13
  epithelial-to-mesenchymal transition (EMT) 5
erectile dysfunction (ED)
  α₁-adrenergic receptor antagonists 75–76, 78–79, 84
  5α-reductase inhibitors 94–95
  combination therapy 148
  epidemiologic studies 11, 14–16
  open simple prostatectomy 169
  phosphodiesterase type 5 inhibitors 114–116, 118–119, 124
  ESRD see end-stage renal disease
  essential fatty acids 160
  estrogens 4
  etiology and pathogenesis 1–9
  androgen regulation 3–4
  biology of BPH/LUTS 2–3
  concepts and definitions 1–2
  estrogen and progesterone regulation 4
  growth factors and chemokines 4–6
  inflammation 6
  need for biomarkers of BPH 7
  pharmacological treatments 1, 2–3
  prostate-associated gene 4 as a stress modulator 6–7
  regulation of the normal prostate 3
  surgical procedures 1, 2
   European Association of Urology (EAU) 23
   European Prospective Investigation into Cancer and Nutrition (EPIC) study 16–17
exercise 13, 160
fatty acids 160
fibroblast growth factor (FGF) 4–5
fibrosis 118–119
finasteride 3, 62, 78, 80–83, 91–96, 134–140
flaxseed lignans 160
flexible cytoscopy 32, 41
formononetin 156
frequency–volume charts (FVC) 40
general practitioners (GPs) 42–44
genistein 156
GreenLight laser therapy 191–200
  60W data 192
  80W data 192–195
  120W data 195–196
  180W 532nm laser 196–197
  532nm wavelength laser 191–192
  adverse effects 193–194, 196, 197–198
  photoselective vaporization of the prostate 191–196
  growth factors 4–6
gynecomastia 95
HDL see high-density lipoprotein
Health Professionals Follow-Up Study (HPFS) 13, 15
health-related quality of life (HRQoL) 26–27
hemorrhage 197
hemostasis 187, 197
high-density lipoprotein (HDL) cholesterol 11, 65
holmium laser enucleation of the prostate (HoLEP) 184, 185–189
holmium laser prostatectomy 184–190
  bladder neck incision 186
  concepts and definitions 184
  equipment 186
  health outcomes 188
  historical development 185
  holmium laser enucleation of the prostate 184, 185–189
  laser physics 185
  lateral lobe enucleation 186–187
  learning curve 188–189
  median lobe enucleation 186
  modifications 187
  morcellation 187
  patient selection 187–188
  procedure 186–187
  technique 185–186
HPFS see Health Professionals Follow-Up Study
HRQoL see health-related quality of life
hypercholesterolemia 119
hyperinsulinemia 5
hypertension 65
hypoxia 118–119
Hypoxis rooperi 159
ICIQ-MLUTS see International Consultation on Incontinence Questionnaire Male LUTS
ICUD see International Consultation on Urologic Diseases
IFIS see intraoperative floppy iris syndrome
IGF see insulin and insulin-like growth factor
IIEF see International Index of Erectile Function
imaging techniques 32, 41, 63
inflammation
  epidemiologic studies 12, 13
  etiology and pathogenesis 6
  watchful waiting 65
informed surveillance 55–56
insulin and insulin-like growth factor (IGF) 4–5
International Consultation on Incontinence Questionnaire Male LUTS (ICIQ-MLUTS) 26–27
International Consultation on Urologic Diseases (ICUD) 23
International Index of Erectile Function (IIEF) 148–149, 169
International Prostate Symptom Score (IPSS)
  α1-adrenergic receptor antagonists 71, 81
  antimuscarinics 104
  clinical assessment and diagnosis 23–26, 39, 44, 50–51
  combination therapy 135–136, 138–140, 143–149
  complementary therapy 155–156, 159–160
  electrocautery-based techniques 203, 206
  GreenLight laser therapy 193–195
  minimally invasive therapies 176, 181
  open simple prostatectomy 168
  phosphodiesterase type 5 inhibitors 121–123
  watchful waiting 60
intraoperative floppy iris syndrome (IFIS) 79–80, 85
IPSS see International Prostate Symptom Score
irritant fluid absorption 197–198
ischemia 119
isoflavones 156
lifestyle factors 13
LSP see laparoscopic simple prostatectomy
macrophages 6
magnetic resonance imaging (MRI) 63
Massachusetts Male Aging Study 65
MCP-1/CCL2 see monocyte chemotactic protein-1
measurement see clinical assessment and diagnosis
median lobe enucleation 186
medical history 23, 38–39, 50–53
Medical Treatment of Prostatic Symptoms (MTOPS)
  α1-adrenergic receptor antagonists 78, 81–83, 85
  combination therapy 136–140
  etiology and pathogenesis 3
  primary care 54
  watchful waiting 63, 66
men who have sex with men (MSM) 14
mesenchyme 2, 5
metabolic syndrome 11–12, 65
minimally invasive therapies 175–183
  adverse effects 180
  botulinum toxin A 179–181
  clinical assessment and diagnosis 25
  concepts and definitions 175–176
  open simple prostatectomy 169–172
  transurethral ethanol ablation of the prostate 178–179, 180
  transurethral microwave thermotherapy 177–178, 180
  transurethral needle ablation of the prostate 176–177, 180
monocyte chemotactic protein-1 (MCP-1/CCL2) 6
monopolar transurethral resection of the prostate (mTURP) 202–203, 207
morcellation 187
MSAM-7 study 14–15
MSM see men who have sex with men
MTOPS see Medical Therapy of Prostatic Symptoms
naftopidil 77–78, 83–84
National Health and Nutrition Examination Survey (NHANES) III 11, 13, 67
nettle root extract 159
neurologic disorders 30
NHANES see National Health and Nutrition Examination Survey
nitric oxide synthase (NOS)/cyclic guanosine monophosphate (cGMP) pathway 116–117
NNT see number-needed-to-treat
nocturia 30, 49–50, 135
nocturnal polyuria 30
nonselective α-blockers 72–73
nonsteroidal anti-inflammatory agents (NSAIDs) 6
NOS/cGMP pathway 116–117
NSAIDs see nonsteroidal anti-inflammatory agents
number-needed-to-treat (NNT) analysis 82–83, 93, 137–138
nutrients 160
OAB see overactive bladder
obesity 11–12
OCAS see oral controlled absorption system
Olmsted County and Flint Michigan Study 12, 60, 62–63, 65
onabotulinumtoxinA (BoNT-ONA) 181
open simple prostatectomy (OSP) 164–174
  concepts and definitions 164
  α1-adrenergic receptor antagonists 71, 81
  antimuscarinics 104
  clinical assessment and diagnosis 23–26, 39, 44, 50–51
  combination therapy 135–136, 138–140, 143–149
  complementary therapy 155–156, 159–160
  electrocautery-based techniques 203, 206
  GreenLight laser therapy 193–195
  minimally invasive therapies 176, 181
  open simple prostatectomy 168
  phosphodiesterase type 5 inhibitors 121–123
  watchful waiting 60
intraoperative floppy iris syndrome (IFIS) 79–80, 85
IPSS see International Prostate Symptom Score
irritant fluid absorption 197–198
ischemia 119
isoflavones 156
lifestyle factors 13
LSP see laparoscopic simple prostatectomy
macrophages 6
magnetic resonance imaging (MRI) 63
Massachusetts Male Aging Study 65
MCP-1/CCL2 see monocyte chemotactic protein-1
measurement see clinical assessment and diagnosis
median lobe enucleation 186
medical history 23, 38–39, 50–53
Medical Treatment of Prostatic Symptoms (MTOPS)
  α1-adrenergic receptor antagonists 78, 81–83, 85
  combination therapy 136–140
  etiology and pathogenesis 3
  primary care 54
  watchful waiting 63, 66
men who have sex with men (MSM) 14
mesenchyme 2, 5
metabolic syndrome 11–12, 65
minimally invasive therapies 175–183
  adverse effects 180
  botulinum toxin A 179–181
  clinical assessment and diagnosis 25
  concepts and definitions 175–176
  open simple prostatectomy 169–172
  transurethral ethanol ablation of the prostate 178–179, 180
  transurethral microwave thermotherapy 177–178, 180
  transurethral needle ablation of the prostate 176–177, 180
monocyte chemotactic protein-1 (MCP-1/CCL2) 6
monopolar transurethral resection of the prostate (mTURP) 202–203, 207
morcellation 187
MSAM-7 study 14–15
MSM see men who have sex with men
MTOPS see Medical Therapy of Prostatic Symptoms
naftopidil 77–78, 83–84
National Health and Nutrition Examination Survey (NHANES) III 11, 13, 67
nettle root extract 159
neurologic disorders 30
NHANES see National Health and Nutrition Examination Survey
nitric oxide synthase (NOS)/cyclic guanosine monophosphate (cGMP) pathway 116–117
NNT see number-needed-to-treat
nocturia 30, 49–50, 135
nocturnal polyuria 30
nonselective α-blockers 72–73
nonsteroidal anti-inflammatory agents (NSAIDs) 6
NOS/cGMP pathway 116–117
NSAIDs see nonsteroidal anti-inflammatory agents
number-needed-to-treat (NNT) analysis 82–83, 93, 137–138
nutrients 160
OAB see overactive bladder
obesity 11–12
OCAS see oral controlled absorption system
Olmsted County and Flint Michigan Study 12, 60, 62–63, 65
onabotulinumtoxinA (BoNT-ONA) 181
open simple prostatectomy (OSP) 164–174
  concepts and definitions 164
functional outcomes 168–169
historical development 164–165
laparoscopic simple prostatectomy 169–170
minimally invasive therapies 169–172
morbidity and mortality 169
perioperative antibiotic prophylaxis 168–169
postoperative management 168
retropubic transcapular prostatectomy 164–165, 166–167
robot-assisted simple prostatectomy 170–172
single-port transvesical enucleation of the prostate 172
suprapubic transvesical prostatectomy 164–165, 166
surgical techniques 166–168
oral controlled absorption system (OCAS) 107
OSP see open simple prostatectomy
overactive bladder (OAB) antimuscarinics 100–103, 104–106
clinical assessment and diagnosis 25, 27, 50
phosphodiesterase type 5 inhibitors 120
oxybutinin 146

PAGE4 see prostate-associated gene 4
pathogenesis see etiology and pathogenesis
patient perception of bladder condition (PPBC) questionnaire 106
patient-reported outcome (PRO) 16
PCPT see Prostate Cancer Prevention Trial
peak urinary flow rate 74
pelvic atherosclerosis 118–119
perineal open simple prostatectomy 165, 167–168
perioperative antibiotic prophylaxis 168–169
phenoxybenzamine 72–73
phosphodiesterase type 5 inhibitors 113–128
adverse effects 123, 149
autonomic hyperactivity 118–119
bladder function 120
chronic hypoxia 118–119
clinical trials 121–123
combination therapy 124–125, 147–149
concepts and definitions 113
epidemiologic studies 114–116
evidence-based outcomes 124
indications and contraindications 124–125
limitations 125
mechanism of action in BPH/LUTS 120–121
NOS/cGMP pathway 116–117
pathophysiology and phosphodiesterase-5 signal pathway 116–119
pelvic atherosclerosis 118–119
prostate function 120
sexual dysfunction 114–116, 118–119, 121, 124–125
sildenafil 121, 124–125, 147–149
spinal cord 121
tadalafil 11, 121–122, 124–125, 148
treatment of LUTS 116
urodynamics 121, 123
vardenafil 120, 122, 149
vasculature 120–121
photoselective vaporization of the prostate (PVP) 191–196
physical examination 27, 39, 53, 62–63, 135
Physicians Health Study 61–62
phytotherapy 155–160
adverse effects 157
β-sitosterol 155–156
Cucurbita pepo L. 160
flaxseed lignans 160
Hypoxis rooperi 159
isoflavones 136
Pygeum africanum 158–159
Secale cereale 159
Serona repens 156–158
Urtica dioica et urens 159
PLESS see Proscar Long-term Efficacy and Safety Study
polyuria 24, 30, 52
postoperative management clinical assessment and diagnosis 53
infections 198
open simple prostatectomy 168
postvoid residual (PVR) antimuscarinics 104–108
clinical assessment and diagnosis 31, 40–41, 53, 54–55
combination therapy 142, 145–147
electrocauterity-based techniques 203–204
GreenLight laser therapy 192–195
minimally invasive therapies 179
PPBC see patient perception of bladder condition
pressure–flow studies 31–32, 41–42
primary care clinical assessment and diagnosis 47–58
concepts and definitions 47–49
degree of bother 55–56
informed surveillance 55–56
initial diagnostic tests 53–55
medical history 50–53
normal/abnormal prostate function 49
physical examination and digital rectal examination 53
reasons for referral 55
PRO see patient-reported outcome
progesterone, etiology and pathogenesis 4
propiverine 142
Proscar Long-term Efficacy and Safety Study (PLESS) 62, 95
Prospective European Doxazosin and Combination Therapy study 80–81, 135–136
prostate-associated gene 4 (PAGE4) 6–7
prostate cancer 5α-reductase inhibitors 93, 95–96
clinical assessment and diagnosis 24, 27, 29, 39–40, 54
combination therapy 138
complementary therapy 156, 160
epidemiologic studies 11–12
etiology and pathogenesis 6
open simple prostatectomy 168
Prostate Cancer Prevention Trial (PCPT) 11–12, 93, 96
prostate-specific antigen (PSA) testing 5α-reductase inhibitors 93–94
clinical assessment and diagnosis 29, 40, 53–54
combination therapy 134–140, 147
watchful waiting growth 62
pumpkin seeds 160
PVP see photoselective vaporization of the prostate
PVR see postvoid residual
Pygeum africanum 158–159
quality of life 23, 26–27
clinical assessment and diagnosis 13, 14, 16
combination therapy 135–136, 146
GreenLight laser therapy 192–193
open simple prostatectomy 168
phosphodiesterase type 5 inhibitors 113, 124
race and ethnicity 12–13
Ras homolog gene family member A/Ras homolog-kinase signaling 116, 117–119
RASP see robot-assisted simple prostatectomy
Reduction by Dutasteride of Clinical Progression Events in Expectant Management trial 95
Reduction by Dutasteride of Prostate Cancer Events (REDUCE) 95–96
renal disease 64–65, 66–67
retrograde ejaculation 198
retropubic transcapular prostatectomy 164–165, 166–167
robot-assisted simple prostatectomy (RASP) 170–172
rye pollen 159
saw palmetto 156–158
SDG see secoisolariciresinol diglucoside
Secale cereale 159
secoisolariciresinol diglucoside (SDG) 160
selective α-blockers 73–78
Serona repens 156–158
serum creatinine 32, 40, 64
sexual dysfunction
α1-adrenergic receptor antagonists 75–76, 78–79, 84
5α-reductase inhibitors 94–95
combination therapy 141–142, 148–149
epidemiologic studies 11, 14–16
GreenLight laser therapy 198
minimally invasive therapies 175, 177, 181
open simple prostatectomy 169
phosphodiesterase type 5 inhibitors 114–116, 118–119, 121, 124–125
Sexual Health Inventory for Male (SHIM) 148
sexuality 14
sexually transmitted infections (STIs) 13, 14
SHIM see Sexual Health Inventory for Male
sildenafil 120, 122, 149
silodosin 76, 79, 85
simple perineal prostatectomy 165, 167–168
single-port transvesical enucleation of the prostate (STEP) 172
sociodemographic factors 13
solifenacin 106, 107
tadinil 5–6
South African star grass 159
spinal cord 121
STEP see single-port transvesical enucleation of the prostate stinging nettle 159
STIs see sexually transmitted infections
stromal–epithelial interactions 4
suprapubic transvesical prostatectomy 164–165, 166
tadalafil 11, 121–122, 124–125, 148
TEAP see transurethral ethanol ablation of the prostate
terazosin 73–74, 80, 85, 134–135
testosterone 3–4, 90–92
TGF see transforming growth factor
TIMES study 104, 142, 146
tolterodine 104–107, 142, 146
transabdominal ultrasound 41
transrectal ultrasound scan (TRUS) 32, 63, 134, 137–138
transurethral electrosurgery of the prostate (TEVP) 203–204
transurethral ethanol ablation of the prostate (TEAP) 178–179, 180
transurethral microwave thermotherapy (TUMT) 177–178, 180
transurethral needle ablation (TUNA) of the prostate 176–177, 180
transurethral resection of the prostate (TURP) 1
adverse effects 202–203, 206
bipolar TURP 204–208
electrocautery-based techniques 201–208
GreenLight laser therapy 192, 194–198
holmium laser prostatectomy 184–189
minimally invasive therapies 177–179
monopolar TURP 202–203, 207
open simple prostatectomy 165, 170
watchful waiting 61–62, 64
transurethral resection (TUR) syndrome 192, 203, 206
transurethral vaporization of the prostate (TUVP) 204
triglycerides 11, 65
TRUS see transrectal ultrasound scan
TUMT see transurethral microwave thermotherapy
TUNA see transurethral needle ablation
TUR see transurethral resection
TURP see transurethral resection of the prostate
United States Preventative Task Force (USPTF) 54
urethral stricture 29, 198
urinalysis 27–29, 40, 53
urinary retention
α1-adrenergic receptor antagonists 83
5α-reductase inhibitors 93
antimuscarinics 104, 106–109
clinical assessment and diagnosis 31, 40
combination therapy 136–140, 145–147
GreenLight laser therapy 192
watchful waiting 61–62
urinary tract infections (UTIs) 29
urodynamics 121, 123, 178
uroflowmetry
clinical assessment and diagnosis 30–31, 31
combination therapy 138, 140, 149
minimally invasive therapies 179, 181
UroLife BPH scale 78–79
Urtica dioica et urens 159
USPTF see United States Preventative Task Force
UTIs see urinary tract infections
VA see Veterans Affairs
vardenafil 120, 122, 149
vasculature dysfunction 120–121
VESIcare In Combination With Tamsulosin in OAB Residual Symptoms study 106
Veterans Affairs (VA) Cooperative Study Group
\( \alpha_1 \)-adrenergic receptor antagonists 80
combination therapy 135
electrocautery-based techniques 202
watchful waiting 62, 64
visual prostate symptom score (VPSS) 16
voiding diaries 28–29, 54

watchful waiting 59–69
acute urinary retention 61–62
autonomic nervous system 66

bladder function changes in men over time 63–64
concepts and definitions 59
diabetes 65
hypertension 65
inflammation 65
metabolic syndrome 65
monitoring renal function in men with BPH 66
presentation and outcomes of BPH progression 59–61
prostate size and growth 62–63
renal disease and BPH 64–65, 66–67
zinc 91, 160